Literature DB >> 24643689

Correlations between the expression levels of micro-RNA146b, 221, 222 and p27Kip1 protein mRNA and the clinicopathologic parameters in papillary thyroid cancers.

F Acibucu1, H S Dökmetaş1, Y Tutar1, S Elagoz1, F Kilicli1.   

Abstract

CONTEXT: It has been shown that miRNA 221, 222 and 146b are increasingly expressed while p27(Kip1) is suppressed in papillary thyroid cancer (PTC).
OBJECTIVE: We investigated the association between the disease recurrence risk and the expression of miRNA 221, 222, 146b and p27(Kip1) protein mRNA in these tumors. We also measured the changes in miRNAs in the presence of Hashimoto's thyroiditis (HT).
METHODS: We examined formalin fixed tissue samples obtained from 77 patients. 11 out of 77 samples were identified as well differentiated tumor with uncertain malignant potential (WDT-UMP), 46 were PTC and 20 were normal thyroid tissue.
RESULTS: Data analysis revealed that the higher risk of recurrence was associated with the higher miRNA expression levels in thyroid cancers. Higher expression levels of miRNA 146b, 221 and 222 were detected in thyroid cancer patients presenting with capsule invasion, vascular invasion or lymph node metastasis, when compared to the patients lacking these features. Furthermore miRNA expression levels were found to be significantly elevated in patients with distant metastases. A negative correlation was found between the p27(Kip1) protein mRNA level and the expression levels of miRNA 221, 222 and 146b. While the expression levels of miRNA 221, 222 and 146b were found to be higher in the cases of WDT-UMP comparing to normal thyroid tissue, the p27Kip1 protein mRNA expression level was lower. No difference was found between the patients with HT and without HT regarding miRNAs expression levels.
CONCLUSIONS: The expression levels of miRNA 221, 222 and 146b were found to be increased in cases of thyroid cancer with a high risk of recurrence. It is important to understand that these molecular changes such as miRNA expression may eventually be used to predict risk of recurrence. © J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24643689     DOI: 10.1055/s-0034-1367025

Source DB:  PubMed          Journal:  Exp Clin Endocrinol Diabetes        ISSN: 0947-7349            Impact factor:   2.949


  14 in total

1.  MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.

Authors:  Julia Ramírez-Moya; León Wert-Lamas; Pilar Santisteban
Journal:  Oncogene       Date:  2018-01-22       Impact factor: 9.867

2.  Identification of soluble tissue-derived biomarkers from human thyroid tissue explants maintained on a microfluidic device.

Authors:  Andrew Riley; Heidi Jones; James England; Dmitriy Kuvshinov; Victoria Green; John Greenman
Journal:  Oncol Lett       Date:  2021-09-13       Impact factor: 2.967

Review 3.  Serum miRNAs as Biomarkers for the Diagnosis and Prognosis of Thyroid Cancer: A Comprehensive Review of the Literature.

Authors:  Mohammad-Reza Mahmoudian-Sani; Ameneh Mehri-Ghahfarrokhi; Majid Asadi-Samani; Gholam-Reza Mobini
Journal:  Eur Thyroid J       Date:  2017-04-07

4.  Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.

Authors:  Patricia Aragon Han; Hyun-seok Kim; Soonweng Cho; Roghayeh Fazeli; Alireza Najafian; Hunain Khawaja; Melissa McAlexander; Benzon Dy; Meredith Sorensen; Anna Aronova; Thomas J Sebo; Thomas J Giordano; Thomas J Fahey; Geoffrey B Thompson; Paul G Gauger; Helina Somervell; Justin A Bishop; James R Eshleman; Eric B Schneider; Kenneth W Witwer; Christopher B Umbricht; Martha A Zeiger
Journal:  Thyroid       Date:  2016-03-07       Impact factor: 6.568

5.  Integrated microRNA, gene expression and transcription factors signature in papillary thyroid cancer with lymph node metastasis.

Authors:  Nurul-Syakima Ab Mutalib; Sri Noraima Othman; Azliana Mohamad Yusof; Shahrun Niza Abdullah Suhaimi; Rohaizak Muhammad; Rahman Jamal
Journal:  PeerJ       Date:  2016-06-15       Impact factor: 2.984

Review 6.  MicroRNAs as Biomarkers in Thyroid Carcinoma.

Authors:  Marilena Celano; Francesca Rosignolo; Valentina Maggisano; Valeria Pecce; Michelangelo Iannone; Diego Russo; Stefania Bulotta
Journal:  Int J Genomics       Date:  2017-09-06       Impact factor: 2.326

7.  Association of MicroRNA Expression and BRAFV600E Mutation with Recurrence of Thyroid Cancer.

Authors:  Daina Pamedytyte; Vaida Simanaviciene; Dalia Dauksiene; Enrika Leipute; Aurelija Zvirbliene; Valdas Sarauskas; Albertas Dauksa; Rasa Verkauskiene; Birute Zilaitiene
Journal:  Biomolecules       Date:  2020-04-17

8.  Plasma Exosomal miR-146b-5p and miR-222-3p are Potential Biomarkers for Lymph Node Metastasis in Papillary Thyroid Carcinomas.

Authors:  Ke Jiang; Genpeng Li; Wenjie Chen; Linlin Song; Tao Wei; Zhihui Li; Rixiang Gong; Jianyong Lei; Hubing Shi; Jingqiang Zhu
Journal:  Onco Targets Ther       Date:  2020-02-13       Impact factor: 4.147

9.  Differential Expression of MicroRNAs in Papillary Thyroid Carcinoma and Their Role in Racial Disparity.

Authors:  Raagini Suresh; Seema Sethi; Shadan Ali; Tamar Giorgadze; Fazlul H Sarkar
Journal:  J Cancer Sci Ther       Date:  2015-05

10.  The Prognostic Value of MicroRNAs in Thyroid Cancers-A Systematic Review and Meta-Analysis.

Authors:  Cristina Alina Silaghi; Vera Lozovanu; Horatiu Silaghi; Raluca Diana Georgescu; Cristina Pop; Anca Dobrean; Carmen Emanuela Georgescu
Journal:  Cancers (Basel)       Date:  2020-09-12       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.